26 September 2025
26 September 2025
The 100% rate on imported, branded pharma products will not apply to drugmakers constructing manufacturing facilities in the US.
The approval was based on results from the Phase III EMBER-3 trial in 256 patients.
Evaxion’s preclinical asset targets an unknown infectious disease in which there are no other vaccines available.
Patients will now be able to access Eliquis and Sotyktu for significantly cheaper than their current list prices.
Lithuania is viewed as a key emerging country in Europe's life sciences ecosystem, with investment in the country on the rise.
Share price in Harmony tumbled in the wake of the Phase III trial miss, with a route to market for ZYN002 looking bleak.
The collaboration will combine Synaffix’s exatecan-based tech with Qurient's CDK7 inhibitor for solid tumour treatments.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
